Critical Comparison: FibroBiologics (FBLG) versus Its Peers

FibroBiologics (NASDAQ:FBLG) is one of 620 publicly-traded companies in the “MED – BIOMED/GENE” industry, but how does it weigh in compared to its peers? We will compare FibroBiologics to related companies based on the strength of its dividends, profitability, risk, institutional ownership, valuation, analyst recommendations and earnings.

Profitability

This table compares FibroBiologics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
FibroBiologics	N/A	-710.25%	-118.02%
FibroBiologics Competitors	-1,418.91%	-791.23%	-29.21%

Institutional and Insider Ownership

51.0% of shares of all “MED – BIOMED/GENE” companies are owned by institutional investors. 20.0% of FibroBiologics shares are owned by insiders. Comparatively, 13.8% of shares of all “MED – BIOMED/GENE” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility and Risk

FibroBiologics has a beta of -0.73, indicating that its stock price is 173% less volatile than the S&P 500. Comparatively, FibroBiologics’ peers have a beta of 0.61, indicating that their average stock price is 39% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and price targets for FibroBiologics and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FibroBiologics	0	0	4	0	3.00
FibroBiologics Competitors	3661	11459	36156	1020	2.66

FibroBiologics currently has a consensus price target of $13.00, suggesting a potential upside of 2,163.63%. As a group, “MED – BIOMED/GENE” companies have a potential upside of 2,307.06%. Given FibroBiologics’ peers higher probable upside, analysts plainly believe FibroBiologics has less favorable growth aspects than its peers.

Valuation and Earnings

This table compares FibroBiologics and its peers revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
FibroBiologics	N/A	-$11.16 million	-1.60
FibroBiologics Competitors	$911.36 million	-$43.78 million	-0.84

FibroBiologics’ peers have higher revenue, but lower earnings than FibroBiologics. FibroBiologics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Summary

FibroBiologics peers beat FibroBiologics on 7 of the 13 factors compared.

About FibroBiologics

FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.